March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Effect of Intravitreal Bevacizumab (Avastin ®) on the Foveal Retinal Thickness in the Injected and Contralateral Eye in a Diverse Clinic Population
Author Affiliations & Notes
  • Jonathan Naysan
    Ophthalmology, North Shore - Long Island Jewish, Great Neck, New York
  • Khurram M. Chaudhary
    Ophthalmology, North Shore - Long Island Jewish, Great Neck, New York
  • Ronni M. Lieberman
    Ophthalmology, North Shore - Long Island Jewish, Great Neck, New York
  • Footnotes
    Commercial Relationships  Jonathan Naysan, None; Khurram M. Chaudhary, None; Ronni M. Lieberman, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2942. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jonathan Naysan, Khurram M. Chaudhary, Ronni M. Lieberman; Effect of Intravitreal Bevacizumab (Avastin ®) on the Foveal Retinal Thickness in the Injected and Contralateral Eye in a Diverse Clinic Population. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2942.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

There has been speculation on the systemic absorption of intravitreal bevacizumab (Avastin ®) in treated patients. This study examines the effect of a single intravitreal injection of bevacizumab (1.25mg/0.05mL) on the foveal retinal thickness (FRT) in both the injected and the contralateral eye in a diverse clinic population.

 
Methods:
 

A retrospective review of 11 patients (22 eyes) who received a single intravitreal injection of bevacizumab was conducted. The foveal retinal thickness was measured using the Zeiss OCT software both before and one month after each patient was treated with a single dose of bevacizumab. Additional data included demographics, diagnoses at time of injection, best corrected visual acuities (BCVA) (converted to logMar) at the time of injection and at 1 month post-injection, and past medical history. Significance was calculated using the Z test.

 
Results:
 

Of the 11 patients, there were 8 Asians, 2 Caucasians, and 1 African American. All of the 11 patients had been diagnosed with clinically significant macular edema (CSME) associated with diabetes. The mean FRT of the injected eyes prior to injection was 321.6µm ± 177.5µm (range, 197 to 552µm). The mean FRT of the contralateral eyes was 335.9µm ± 515.5µm (range, 121 to 1152µm). At one month post injection, the mean FRT of the injected eye showed an 18.6% decrease from baseline to a mean of 261.6µm ± 172µm (p=0.6317). The contralateral eye group showed a decrease of 0.7% to a mean of 333.6µm ± 508µm (p=0.6064).

 
Conclusions:
 

We found an expected decrease in overall retinal thickness in the injected eye at one month post injection. In the contralateral eye there was an overall decrease in FRT which was not found to be significant. Although minimal systemic absorption of bevacizumab has been documented, which may effect the contralateral eye initially, there does not appear to be an effect at one month. Further study is needed investigating the effects of multiple bevacizumab injections with a longer period of follow up, in addition to early (1 to 7 days) effects on the contralateral eye. These findings may further contribute to the safety profile of intravitreal bevacizumab.

 
Keywords: drug toxicity/drug effects • macula/fovea • edema 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×